Chemodex

2-Chloro-2'-deoxyadenosine

Out of stock
Only %1 left
NEW
 
More Information
Product Details
Synonyms CdA; Cladribine; 2-Chlorodeoxyadenosine; 2-Chloro-2′-deoxy-β-adenosine; NSC 105014-F; RWJ 26251
Product Type Chemical
Properties
Formula C10H12ClN5O3
MW 285.69
CAS 4291-63-8
RTECS AU7357560
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (10mg/ml) or DMF (10mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key PTOAARAWEBMLNO-KVQBGUIXSA-N
Smiles NC1=C2C(N(C=N2)[C@@H]3O[C@H](CO)[C@@H](O)C3)=NC(Cl)=N1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description
2-Chloro-2′-deoxyadenosine is a synthetic anticancer purine nucleoside analog commonly used in biochemical and cellular research to study nucleoside metabolism, DNA synthesis, and apoptosis pathways. Due to its resistance to adenosine deaminase–mediated degradation, this compound exhibits enhanced stability in biological systems, making it a valuable tool for mechanistic studies involving DNA replication and repair. Cladribine is cytotoxic to resting or proliferating lymphocytes. It inhibits RNA synthesis and induces DNA strand breaks in resting human peripheral blood lymphocytes. Cladribine induces cell cycle arrest at the G1 phase and apoptosis in U266, RPMI-8226, and MM.1S multiple myeloma cells in a concentration-dependent manner. It reduces tumor growth in HT-29 colon cancer, RL lymphoma, and RPMI-8226 multiple myeloma mouse xenograft models.
Product References
[1] D.A. Carson, et al.; Blood 62, 737 (1983) | [2] S. Seto, et al.; J. Clin. Invest. 75, 377 (1985) | [3] E. Beutler; Lancet 340, 952 (1992) (Review) | [4] A. Gorski, et al.; Immunopharmacol. 26, 197 (1993) | [5] S. Spurgeon, et al.; Expert Opin. Investig. Drugs 18, 1169 (2009) (Review) | [6] J. Ma, et al.; BMC Cancer 11, 255 (2011) | [7] T.P. Leist & R. Weissert; Clin. Neuropharmacol. 34, 28 (2011) (Review) | [8] R. Hermann, et al.; Clin. Pharmacokinet. 60, 1509 (2021) (Review) | [9] R. Hermann, et al.; Clin. Pharmacokinet. 61, 167 (2022) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.